News for Orexo AB (publ) (ORXOY)

PR NewswireUPPSALA, Sweden, June 2, 2025 OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (i

PR NewswireUPPSALA, Sweden, April 10, 2025 The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 year

PR NewswireUPPSALA, Sweden, Jan. 10, 2025 OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. a

Orexo Interim Report Q3 2024

Orexo ´s Nomination Committee for the Annual General Meeting 2025

Orexo AB ´s sustainability work ranked among top 5% by EcoVadis

Orexo Q1 2024 Interim Report

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Orexo publishes the Annual and Sustainability Report for 2023

UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m EBITDA of SEK 12.4 m , EBITDA excluding...

Big step forward in launching OX124 in the US UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights›     Total net revenues of SEK 156.1 m ›     EBITDA of SEK -9.5 m , EBITDA...

UPPSALA, Sweden, Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders having...

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further...

Orexo AB (publ.), (

UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ('Orexo' or the 'Company') (STO:ORX) (OTCQX:ORXOY) has successfully issued senior ...

/PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income...

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of opioid overdose. The US Patent and Trademark Office (USPTO) has issued a new patent protecting the product until 2039.

Pune, India, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The global opioid use disorder market is expected to experience exponential growth by reaching USD 4.87 ...